UPDATE: Finish Line (FINL) Misses Q3 EPS by 11c, Comps Up 3.6%; Cuts FY12 EPS Outlook
Get Alerts FINL Hot Sheet
Price: $13.51 --0%
Financial Fact:
Income from continuing operations before income taxes: 34.88M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Income from continuing operations before income taxes: 34.88M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
(Updated - January 4, 2013 7:37 AM EST)
Finish Line (NASDAQ: FINL) reported Q3 EPS of $0.00, $0.11 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $296.6 million versus the consensus estimate of $298.48 million.
Comps rose 3.6 percent.
Finish Line sees Q4 2013 EPS of $0.74-$0.78, versus the consensus of $0.82.
Finish Line sees FY2013 EPS of $1.47-$1.51, versus the consensus of $1.64. The number is below prior expectations for 6 percent to 9 percent growth over $1.53 reported in FY12.
For earnings history and earnings-related data on Finish Line (FINL) click here.
Finish Line (NASDAQ: FINL) reported Q3 EPS of $0.00, $0.11 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $296.6 million versus the consensus estimate of $298.48 million.
Comps rose 3.6 percent.
Finish Line sees Q4 2013 EPS of $0.74-$0.78, versus the consensus of $0.82.
Finish Line sees FY2013 EPS of $1.47-$1.51, versus the consensus of $1.64. The number is below prior expectations for 6 percent to 9 percent growth over $1.53 reported in FY12.
For earnings history and earnings-related data on Finish Line (FINL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Retail SalesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share